english.prescrire.org > Spotlight > 100 most recent > High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the February issue of Prescrire International - High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

FREE DOWNLOAD In the Adverse Effects section this month: should patients taking a direct oral anticoagulant switch to a vitamin K agonist such as warfarin, in light of the French drug regulatory agency's recent advisory?
Full text available for free download.

Summary

  • In mid-2019, the French drug regulatory agency, ANSM, advised health professionals not to use direct oral anticoagulants in patients with a history of thrombosis and known to have antiphospholipid antibodies.
     
  • Given the increased risk of thrombosis in patients with antiphospholipid antibodies who take rivaroxaban, it makes sense to avoid direct oral anticoagulants in this situation, and to choose warfarin instead.

Full text available for free download.

 ©Prescrire 1 February 2020

"High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants" Prescrire Int 2020; 29 (212): 43. (Pdf, free).

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free